metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Trichomonas vaginalis: tratamiento y resistencia a nitroimidazoles
Información de la revista
Vol. 19. Núm. 3.
Páginas 114-124 (marzo 2001)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 19. Núm. 3.
Páginas 114-124 (marzo 2001)
Acceso a texto completo
Trichomonas vaginalis: tratamiento y resistencia a nitroimidazoles
Visitas
154630
Fernando Vázqueza,1
Autor para correspondencia
fvazquez@correo.uniovi.es
fvazquez@hmm.es

Correspondencia: Dr. F. Vázquez Valdés. Departamento de Biología Funcional. Área de Microbiología. Facultad de Medicina. Universidad de Oviedo. C./ Julián Clavería s/n. 33006 Oviedo.
, Ma José Garcíab, Francisco Pérezb, Virgilio Palacioc
a Departamento de Biología Funcional. Área de Microbiología. Facultad de Medicina de Oviedo y Servicio de Microbiología. Hospital Monte Naranco
b Servicio de Microbiología. Hospital Central de Asturias
c Servicio de Dermatología y Enfermedades de Transmisión Sexual. Hospital Monte Naranco. Oviedo
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R.E. Trussell.
Trichomonas vaginalis and trichomoniasis.
Charles C. Thomas, (1947),
[2.]
K. Maeda, T. Osata, H. Umeza.
A new antibiotic, azomycin.
J Antibiot, 6 (1953), pp. 182
[3.]
C.D. Freeman, N.E. Klutman, K.C. Lamp.
Metronidazole. A therapeutic review and update.
Drugs, 54 (1997), pp. 679-708
[4.]
C. Cosar, L. Julou.
Activité de l’(hydroxy-2-éthyl)-1-méthyl-2-nitro-5-imidazole (8823 R.P.) vis-à-vis des infections expérimentales à trichomonas vaginalis.
Ann Inst Pasteur, 96 (1959), pp. 238-241
[5.]
P. Durel, V. Roiron, H. Siboulet, L.J. Borel.
Trial of an antitrichomonal derivate of imidazole (8823 R.P.) Comptes Rendus Soc Franç Gynécol, 29 (1959), pp. 36
[6.]
P. Durel, V. Roiron, A. Siboulet, L.J. Borel.
Systemic treatment of human trichomoniasis with a derivative of nitro-imidazole, 8823 R. P.
Br J Vener Dis, 36 (1960), pp. 21-26
[7.]
D.I. Edwards.
Nitroimidazole drugs-action and resistance mechanisms. I. Mechanisms of action.
J. Antimicrob Chemother, 31 (1993), pp. 9-20
[8.]
H.L. Howes, J.E. Lynch, J.L. Kiulin.
Tinidazole, a new antiprotozoal agent: Effect on Trichomonas and other protozoa.
Antimicrob Agents Chemother, 9 (1969), pp. 261-266
[9.]
J. Wallin, A. Forsgren.
Tinidazole – a new preparation for Trichomonas vaginalis infections. II. Clinical evaluation of treatment with a single oral dose.
Br J Vener Dis, 50 (1974), pp. 148-150
[10.]
L. Hillström, L. Petterson, E. Pálsson.
Comparison of ornidazole and tinidazole in single- dose treatment of trichomoniasis in women.
Br J Vener Dis, 53 (1977), pp. 193-194
[11.]
R. Jones, P. Enders.
An evaluation of tinidazole as single- dose therapy for the treatment of Trichomonas vaginalis.
Med J Aust, 2 (1977), pp. 679-680
[12.]
N. Kawamura.
Metronidazole and tinidazole in a single large dose for treating urogenital infections with Trichomonas vaginalis in man.
Br J Vener Dis, 54 (1978), pp. 81-83
[13.]
M.W. Miller, H.L. Howes, A.R. English.
Tinidazole, a potent new antiprotozoal agent.
Antimicrob Agents Chemother, 169 (1970), pp. 257-260
[14.]
F. Vázquez Valdés.
Tricomoniasis (Ponencia).
pp. 27-29
[15.]
D.H.H. Robertson, R. Heyworth, C. Harrison, W.R.H. Lumsden.
Treatment failure in Trichomonas vaginalis infections in females. I. Concentrations of metronidazole in plasma and vaginal content during normal and high dosage.
J Antimicrob Chemother, 21 (1988), pp. 373-378
[16.]
M. Sköld, H. Gnarpe, L. Hillström.
Ornidazole: A new antiprotozoal compound for treatment of Trichomonas vaginalis infections.
Br J Vener Dis, 53 (1977), pp. 44-48
[17.]
J. Symonds.
Secnidazole- a nitroimidazole with a prolonged serum halflife.
J Antimicrob Chemother, 5 (1979), pp. 484-486
[18.]
A/ Notowicz, E. Stolz, G.A.J. de Koning.
First experiences with single- dose treatment of vaginal trichomoniasis with carnidazole (R25831).
Br J Vener Dis, 53 (1977), pp. 129-131
[19.]
A. Cantone, I. de Carneri, A. Emanueli, P.N. Giraldi, W. Logemann, R. Longo, G. Meinardi, G. Monti, G. Nannini, G. Tosolini, G. Vita.
Nitroimidazole: A new systemic trichomonacide.
G Mal Infett Parassit, 21 (1969), pp. 954-958
[20.]
R.R. Willcox.
How suitable are available pharmaceuticals for the treatment of sexually transmited diseases? 1. Conditions presenting as genital discharges.
Br J Vener Dis, 53 (1977), pp. 314-323
[21.]
J.A. Uprcroft, R.A. Campbell, K. Benakli, P. Upcroft, P. Vanelle.
Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and–resistant Giardia, Trichomonas, and Entamoeba spp.
Antimicrob Agents Chemother, 43 (1999), pp. 73-76
[22.]
D.M. Brown, J.A. Upcroft, P. Upcroft.
An alternative keto acid oxidoreductase in Trichomonas vaginalis.
Mol Biochem Parasitol, 98 (1999), pp. 203-214
[23.]
S.M. Townson, P.F.L. Boreham, P. Upcroft, J.A. Upcroft.
Resistance to the nitroheterocyclic drugs.
Acta Trop, 56 (1994), pp. 173-194
[24.]
S.M. Townson, J.A. Upcroft, P. Upcroft.
Characterisation and purification of pyruvate: ferredoxin oxidoreductase from Giardia duodenalis.
Mol Biochem Parasitol, 79 (1996), pp. 183-193
[25.]
Boreham PFL, Smith NC, Shepherd RW. Drug resistance and the treatment of giardiasis. En: Wallis PM, Hammond BR (ed.). Advances in Giardia research. University of Calgary Press, Calgary, Alberta, Canadá.
[26.]
J.A. Upcroft, P. Upcroft.
Drug resistance and Giardia.
Parasitol Today, 4 (1993), pp. 187-190
[27.]
M. Müller.
Mode of action of metronidazole an anaerobic bacteria and protozoa.
Surgery, 993 (1983), pp. 165-171
[28.]
M.O. Robbie, R.L. Sweet.
Metronidazole use in obstetrics and gynecology: A review.
Am J Obstet Gynecol, 145 (1983), pp. 865-881
[29.]
D.G. Lindmark, M. Müller, H. Shio.
Hydrogenosomes in Trichomonas vaginalis.
J Parasitol, 61 (1975), pp. 552-554
[30.]
M. Müller.
The hydrogenosome.
J Gen Microbiol, 139 (1993), pp. 2.879-2.889
[31.]
E.M. Narcisi, W.E. Sector.
In vitro effect of tinidazole and furazolidone on metronidazole- resistant Trichomonas vaginalis.
Antimicrob Agents Chemother, 40 (1996), pp. 1.121-1.125
[32.]
M. Müller.
Reductive activation of nitroimidazole in anaerobic microorganisms.
Biochemical Pharm, 35 (1986), pp. 37-41
[33.]
W.H.R. Lumsdem, D.H.H. Robertson, R. Heyworth, C. Harrison.
Treatment failure in Trichomonas vaginalis vaginitis.
Genitourin Med, 64 (1988), pp. 217-218
[34.]
J.A. McFadzean, I.M. Pugh, S.L. Squires, J.P.F. Whelan.
Further observations on strain sensitivity of Trichomonas vaginalis to metronidazole.
Br J Vener Dis, 45 (1969), pp. 161-162
[35.]
D.I. Edwards, E.J. Thompson, J. Tomusagne, D. Shanson.
Inactivation of metronidazole by aerobic organisms.
J Antimicrob Chemother, 5 (1979), pp. 315-316
[36.]
F. Wilmott, J. Say, D. Downey, A. Hookam.
Zinc and recalcitrant trichomoniasis.
Lancet, i (1983), pp. 1.053
[37.]
A. Barbeau, J. Donaldson.
Zinc, taurine and epilepsy.
Arch Neurol, 30 (1974), pp. 52-58
[38.]
G.D. Schott, H.T. Delues.
Plasma zinc levels with anticonvulsant therapy.
Br J Clin Pharmacol, 5 (1978), pp. 279-280
[39.]
S.C. Robinson.
Trichomonal vaginitis resistant to metronidazole.
Can Med Assoc J, 86 (1962), pp. 665
[40.]
J.G. Meingassner, J. Thurner.
Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles.
Antimicrob Agents Chemother, 15 (1979), pp. 254-257
[41.]
M. Müller, J.G. Meingassner, W.A. Miller, W.J. Ledger.
Three metronidazoleresistant strains of Trichomonas vaginalis from the United States.
Am J Obstet Gynecol, 138 (1980), pp. 808-812
[42.]
J. Kulda, M. Vojtěchowská, J. Tachezy, P. Demed, E. Kunzová.
Metronidazole resistance of Trichomonas vaginalis as a cause of treatment failure in trichomoniasis.
Br J Vener Dis, 58 (1982), pp. 394-399
[43.]
M.S. Sprott, A.M. Kearms, R.S. Pattman.
Trichomonal vaginitis refractory to treatment: Case report.
Genitourin Med, 64 (1988), pp. 369-372
[44.]
D.I. Edwards.
Nitroimidazole drugs- action and resistance mechanisms. II. Mechanisms of resistance.
J Antimicrob Chemother, 31 (1993), pp. 201-210
[45.]
K.A. Borchardt, Z. Li, M.Z. Zhang, H. Shing.
An in vitro metronidazole susceptibility test for trichomoniasis using the InPouch TV test.
Genitourin Med, 72 (1996), pp. 132-135
[46.]
B. Korner, H.K. Jensen.
Sensitivity of Trichomonas vaginalis to metronidazole, tinidazole, and nifurantel in vitro.
Br J Vener Dis, 52 (1976), pp. 404-408
[47.]
J.G. Meingassner, L. Havelec, H. Mieth.
Studies on strain sensitivity of Trichomonas vaginalis to metronidazole.
Br J Vener Dis, 54 (1978), pp. 72-76
[48.]
J.G. Lossick, M. Müller, T.E. Gorrell.
In vitro drug susceptibility and dose of metronidazole required for cure in cases of refractory vaginal trichomoniasis.
J Infect Dis, 153 (1986), pp. 948-955
[49.]
T. Meri, T.S. Jokiranta, L. Suhonen, S. Meri.
Resistance of Trichomonas vaginalis to metronidazole: Report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations.
J Clin Microbiol, 38 (2000), pp. 763-767
[50.]
M. Müller, J.G. Lossick, T.E. Gorrell.
In vitro susceptibility of Trichomonas vaginalis to metronidazole and treatment outcome in vaginal tricomoniasis.
Sex Transm Dis, 15 (1988), pp. 17-24
[51.]
J. Tachezy, J. Kulda, E. Tomkova.
Aerobic resistance of Trichomonas vaginalis to metronidazole induced in vitro.
Parasitol, 106 (1993), pp. 31-37
[52.]
R. Heyworth, D. Simpson, G.J.C. McNeillage, D.H.H. Robertson, H. Young.
Isolation of Trichomonas vaginalis resistant to metronidazole.
Lancet, 2 (1980), pp. 476-478
[53.]
A. Cerkasovová, J. Cerkasov, J. Kulda.
Resistance of trichomonads to metronidazole.
Acta Univ Carolinae- Biol, 30 (1988), pp. 485-503
[54.]
J. Kulda.
Trichomonads, hidrogenosomes and drug resistance.
Int J Parasitol, 29 (1999), pp. 199-212
[55.]
M. French, S. Krajden, J.G. Lossick, E. Wilk, J. Yang, J.S. Keystone, K. Elliot.
Persistent Trichomonas vaginalis infection due to a metronidazole-resistant strain.
CAMJ, 134 (1986), pp. 1.373-1.374
[56.]
N. Yarlett, N.C. Yarlett, D. Lloyd.
Ferrodoxin- dependent reduction of nitroimidazole derivates in drug resistant and susceptible strains of Trichomonas vaginalis.
Biochem Pharmacol, 35 (1985), pp. 1.703-1.708
[57.]
D. Quon, C. d’Oliveira, P. Johnson.
Reduced transcription of the ferredoxin gene in metronidazole resistant Trichomonas vaginalis.
Proc Natl Acad Sci USA, 89 (1992), pp. 4.402-4.406
[58.]
S.D. Sears, J. O’Hare.
In vitro susceptibility of Trichomonas vaginalis to 50 antimicrobial agents.
Antimicrob Agents Chemother, 32 (1988), pp. 1044-1146
[59.]
C.T. King, R.W. Finley, W.B. Lushbaugh.
Quinolones lack efficacy for treatment of trichomoniasis.
J Infect Dis, 164 (1991), pp. 624-625
[60.]
L. Gershenfeld.
Povidone-iodine (PVP-I) as a trichomonicide.
Am J Pharm, 334 (1962), pp. 324-331
[61.]
T. Lövgren, I. Salmela.
In vitro sensitivity of Trichomonas vaginalis and Candida albicans to chemotherapeutic agents.
Acta Pathol Microbiol Scand Sect B, 86 (1978), pp. 155-158
[62.]
C.H. Livengood, J.G. Lossick.
Resolution of resistant vaginal trichomoniasis associated with the use of intravaginal nonoxynol-9.
Obstet Gynecol, 78 (1991), pp. 954-956
[63.]
J.A. Escario, A.M. Igea, M. Contreras, A.R. Martínez-Fernández, R. Claramunt, C. López.
Antiparasitic activity of nine pyrazole derivatives against Trichomonas vaginalis, Entamoeba invadiens, and Plasmodium berghei.
Ann Trop Med Parasitol, 82 (1988), pp. 257-262
[64.]
A. Herrero, C. Ochoa, J. Atienza, J.A. Escario, A. Gómez-Barrio, A.R. Martínez Fernández.
Synthesis and antiprotozoal properties of 1,2,6-thiadiazine 1,1-dioxide derivatives.
Arch Pharm (Weinheim), 325 (1992), pp. 509-514
[65.]
S.K. Katiyar, T.D. Edlind.
Enhanced antiparasitic activity of lipophilic tetracyclines: Role of uptake.
Antimicrob Agents Chemother, 35 (1991), pp. 2.198-2.202
[66.]
Y. Kaneda, T. Tanaka, T. Saw.
Effects of berberibe, a plant alkaloid, on the growth of anaerobic protozoo in axenic culture.
Tokai J Exp Clin Med, 15 (1990), pp. 417-423
[67.]
Y. Kaneda, M. Torii, T. Tanakat, M. Aikawa.
In vitro effects of berberine sulphate on the growth and structure of Entamoeba histolytica, Giardia lamblia, and Trichomonas vaginalis.
Ann Trop Med Parasitol, 85 (1991), pp. 417-425
[68.]
J.D. Sobel, V. Nagappan, P. Nyiersjesy.
Metronidazole-resistant vaginal trichomoniasis- an emerging problem.
N Engl J Med, 341 (1999), pp. 292-293
[69.]
M. Valent, M. Klobusicky, L. Mokova, M. Karvaj, A. Janoska.
Study of Trichomonas vaginalis resistance to metronidazole SPOFA.
Bratisl Lek Listy, 68 (1977), pp. 277-281
[70.]
B.A. Dijkmans, A.M. Polderman, A.P. Heintz, R. van Furth.
A strain of Trichomonas vaginalis with reduced sensitivity for metronidazole.
Ned Tijdschr Geneeskd, 126 (1982), pp. 2.193-2.195
[71.]
T. Giannone.
Study on increased resistance to metronidazole in Trichomonas vaginalis strains in Lombardy.
Minerva Ginecol, 24 (1972), pp. 354-355
[72.]
P. Bergsjo.
Reduced sensitivity of Trichomonas vaginalis to metronidazole.
Tidsskr Nor Laegeforen, 99 (1979), pp. 336
[73.]
A. Kurnatowska.
Metronidazole resistance of Trichomonas vaginalis Donne.
Wiad Parazytol, 15 (1969), pp. 399-401
[74.]
L.M. Korik.
Strains of Trichomonas vaginalis resistant to metronidazole. Vestn Dermatol Venerol 1971; 45: 77-80. 75. Waitkins SA, Thomas DJ. Isolation of Trichomonas vaginalis resistant to metronidazole.
Lancet, 45 (1971), pp. 77-80
[75.]
S.A. Waitkins, D.J. Thomas.
Isolation of Trichomonas vaginalis resistant to metronidazole.
Lancet, 2 (1981), pp. 590
[76.]
A. Forsgren, L. Forssman.
Metronidazol-resistant Trichomonas vaginalis.
Br J Vener Dis, 55 (1979), pp. 351-353
[77.]
J. Thurner, J.G. Meingassner.
Isolation of Trichomonas vaginalis resistant to metronidazole.
Lancet, 2 (1978), pp. 738
[78.]
J.G. Lossick, H.L. Kent.
Tricomoniasis: trends in diagnosis and management.
Am J Obstet Gynecol, 165 (1991), pp. 1.217-1.222
[79.]
J.H. Grossman, R.P. Galask.
Persistent vaginitis caused by metronidazoleresistant trichomonas.
Obstet Gynecol, 76 (1990), pp. 521-522
[80.]
I.H. Ahmed-Jushuf, A.E. Murray, J. McKeown.
Managing trichomonal vaginitis refractory to conventional treatment with metronidazole.
Genitourin Med, 64 (1988), pp. 25-29
[81.]
T. Voolman, P. Boreham.
Metronidazole resistant Trichomonas vaginalis in Brisbane (letter).
Med J Aus, 159 (1993), pp. 490
[82.]
K.A. Hamed, A.E. Studemeister.
Successful response of metronidazole-resistan trichomonal vaginitis to tinidazole.
Sex Transm Dis, 19 (1992), pp. 339-340
[83.]
M.P. Dombrowski, R.J. Sokol, W.J. Brown, R.A. Bronsteen.
Intravenous therapy of metronidazole-resistant Trichomonas vaginalis.
Obstet Gynecol, 69 (1987), pp. 524-525
[84.]
D.J. Keilock, C.P. O’Mahoney.
Sexually acquired metronidazole- resistant trichomoniasis in a lesbian couple.
Genitourin Med, 72 (1996), pp. 60-61
[85.]
P. Nyirjesy, J.D. Sobel, M.V. Weitz, D.J. Leaman, S.P. Gelone.
Difficult-to-treat trichomoniasis: Results with paromomycin cream.
Clin Infect Dis, 26 (1998), pp. 968-988
[86.]
P. Nyirjesy, M.V. Weitz, S.P. Gelone, T. Feket.
Paramomycin for nitroimidazole- resistant trichomonosis.
Lancet, 346 (1995), pp. 1.110
[87.]
D.D. Coelho.
Metronidazole resistant trichomoniasis sucessfully treated with paromomycin.
Genitourin Med, 73 (1997), pp. 397-398
[88.]
R.M. van der Weiden, W.I. van de, D.H. Bogchelman, A.M. Polderman.
Treatment failure in trichomoniasis and persistence of the parasites after Lactobacillus inmunotherapy; two case reports.
Eur J Obstet Gynecol Reprod Biol, 34 (1990), pp. 171-178
[89.]
E.I. Ikeh, C.S. Bello, J.A. Ajayi.
In vitro susceptibility of Trichomonas vaginalis strains to metronidazole- a Nigerian experience.
Genitourin Med, 69 (1993), pp. 241-242
[90.]
J.G. Lossick.
Therapy of urogenital trichomoniasis.
Trichomonads Parasitic in Humans, pp. 326-341
[91.]
British Co-operative Clinical Group. An investigation, by questionnaire, of cases of recalcitrant vaginal trichomoniasis seen in genitourinary medicine clinics in the United Kingdom.
Int J STD AIDS, 3 (1992), pp. 24-27
[92.]
F.J.C. Roe.
Metronidazole: review of uses and toxicity.
J Antimicrob Chemother, 3 (1977), pp. 205-212
[93.]
CID. Metronidazole-resistant Trichomonas vaginalis.
Clin Infect Dis, 29 (1999),
[94.]
Pérez S, Fernández-Verdugo A, Pérez F, Vázquez F. Prevalence of 5-nitroimidazoles- resistant Trichomonas vaginalis in Oviedo (Spain). Sex Transm Dis 2001; 28 (en prensa).
[95.]
F. Sorvillo, P. Kerndt.
Trichomonas vaginalis and amplification of HIV- 1 transmission.
[96.]
P. Heine, J.A. McGregor.
Trichomonas vaginalis: a reeemerging pathogen.
Clin Obstet Gynecol, 36 (1993), pp. 137-144
[97.]
J.D. Sobel.
Management of vaginosis: prevention and treatment.
Drug Invest, 8 (1994), pp. 26-34
[98.]
G.W. Csonka.
Trichomonal vaginitis treated with one dose of metronidazole.
Br J Vener Dis, 47 (1971), pp. 456-458
[99.]
K.R. Woodcock.
Treatment of trichomonal vaginitis with a single oral of metronidazole.
Br J Vener Dis, 48 (1972), pp. 65-68
[100.]
R.S. Morton.
Metronidazole in the single-dose treatment of trichomoniasis in mend and women.
Br J Vener Dis, 48 (1972), pp. 525-527
[101.]
R.N. Thin, M.A.E. Symonds, R. Booker, S. Cook, F. Langlet.
Double-blind comparison of a single dose and a five-day course of metronidazole in the treatment of trichomoniasis.
Br J Vener Dis, 55 (1979), pp. 354-356
[102.]
W.D. Hager, S.T. Brown, S.J. Krauss, G.S. Kleris, G.J. Perkins, M. Henderson.
Metronidazole for vaginal trichomoniasis. Seven days vs. single dose regimen.
JAMA, 244 (1980), pp. 1.219-1.220
[103.]
E.D. Ralph, R. Darwish, T.W. Austin, E.A. Smith, F.L.M. Pattison.
Susceptibility of Trichomonas vaginalis strains to metronidazole: Response to treatment.
Sex Transm Dis, 10 (1983), pp. 119-122
[104.]
P. O-Prasertsawat, T. Jetsawangsri.
Split-dose metronidazole or singledose tinidazole for the treatment of vaginal trichomoniasis.
Sex Transm Dis, 19 (1992), pp. 295-297
[105.]
M.R. Spence, T.S. Harwell, M.C. Davies, J.L. Smith.
The minimum single oral metronidazole dose for treating trichomoniasis: A randomized, blinded study.
Obstet & Gynecol, 89 (1997), pp. 699-703
[106.]
N. Kawamura.
Metronidazole and tinidazole in a single large dose for treating urogenital infections with Trichomonas vaginalis in men.
Br J Vener Dis, 54 (1978), pp. 81-83
[107.]
R.A. Underhill, J.E. Peck.
Causes of therapeutic failure after treatment of trichomonal vaginitis with metronidazole: Comparison of single-dose treatment with a standar regimen.
Br J Clin Pract, 28 (1974), pp. 134-136
[108.]
J.R. Dykers.
Single-dose metronidazole for trichomonal vaginitis.
N Engl J Med, 293 (1975), pp. 23-24
[109.]
F.J. Fleuryvan, W.S. Bergen, R.L. Prentice, J.G. Russell, J.A. Singleton, J.V. Standard.
Single dose of two grams of metronidazole for Trichomonas vaginalis infection.
Am J Obstet Gynecol, 128 (1997), pp. 320-322
[110.]
B.H. Tidwell, W.B. Lushbaugh, M.D. Laughlin, J.D. Cleary, R.W. Finley.
A double-blind placebo-controlled trial of single-dose intravaginal versus single-dose oral metronidazole in the treatment of trichomonal vaginitis.
J Infect Dis, 170 (1994), pp. 242-246
[111.]
P. Rodin, G. Hass.
Flagyl in the treatment of trichomoniasis.
Br J Vener Dis, 36 (1960), pp. 147-149
[112.]
J.N. Krieger, J.F. Alderete.
Trichomonas vaginalis and trichomoniasis.
Sexually Transmitted Diseases (3th edition), pp. 587-604
[113.]
P. Durel, J. Couture, P. Collart, G. Girot.
Flagyl metronidazole.
Br J Vener Dis, 36 (1960), pp. 154-162
[114.]
R.D. Catterall.
Trichomonal infections of the genital tract.
Med Clin North Am, 56 (1972), pp. 1.203-1.209
[115.]
Centers for Disease Control and Prevention. 1993 sexuallly transmitted diseases treatment guidelines.
MMWR, 42 (1993), pp. 70-72
[116.]
S.K. Panja.
Treatment of trichomoniasis with metronidazole rectal suppositories.
Br J Vener Dis, 58 (1982), pp. 257-258
[117.]
T.W. Austin, E.A. Smith, R. Darwish, E.D. Ralph, F.L.M. Pattison.
Metronidazole in a single dose for the treatment of trichomoniasis: Failure of a 1-g single dose.
Br J Vener Dis, 58 (1982), pp. 121-123
[118.]
D.E. Soper.
Bacterial vaginosis and trichomoniasis: epidemiology and management of recurrent disease.
Infect Dis Obstet Gynecol, 2 (1995), pp. 242-247
[119.]
L. duBouchet, J.A. McGregor, M. Ismail, W.M. McCormack.
A pilot study of metronidazole vaginal gel versus oral metronidazole for the treatment of Trichomonas vaginalis vaginitis.
Sex Transm Dis, 25 (1998), pp. 176-179
[120.]
A.J. Pereyra, J.D. Lansing.
Urogenital trichomoniasis: treatment with metronidazole in 2002 incarcerated women.
Obstet Gynecol, 24 (1964), pp. 499-508
[121.]
Centers for Disease Control and Prevention. 1998 guidelines for treatment of sexually transmitted diseases.
MMWR, 47 (1998), pp. 74-75
[122.]
A.R. Wisdom, E.M.C. Dunlop.
Trichomoniasis: Study of the disease and its treatment: II. The disease and its treatment in men.
Br J Vener Dis, 41 (1965), pp. 93-95
[123.]
A.S. Latif, P.R. Mason, E. Marowa.
Urethral trichomoniasis in men.
Sex Transm Dis, 14 (1987), pp. 9-11
[124.]
J.N. Krieger, M. Verdon, N. Siegel, K.K. Holmes.
Natural history of urogenital trichomoniasis in men.
J Urol, 149 (1993), pp. 1.455--1.458
[125.]
J.M. Aubert, H.J. Sesta.
Treatment of vaginal trichomoniasis: Single, 2- gram dose of metronidazole as compared with a seven-day course.
J Reprod Med, 27 (1982), pp. 743-745
[126.]
G. Gabriel, E. Robertson, R.N.T. Thin.
Single dose treatment of trichomoniasis.
J Int Med Res, 10 (1982), pp. 129-130
[127.]
V. Palacio López, F. Vázquez Valdés.
Vaginitis por Trichomonas vaginalis.
Programa Nacional para la actualización de las ETS y SIDA (Tomo I), pp. 366-382
[128.]
F.E. Cunningham, D.M. Kraus, L. Brubaker, J.H. Fischer.
Pharmacokinetics of intravaginal metronidazole gel.
J Clin Pharmacol, 34 (1994), pp. 1.060-1.065
[129.]
L. duBouchet, M.R. Spence, M.F. Rein, M.R. Danzing, M.W. McCormack.
Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrichloride, and allantoin in the treatment of symptomatic trichomoniasis.
Sex Transm Dis, 24 (1997), pp. 156-160
[130.]
M. Dan, J.D. Sobel.
Trichomoniasis as seen in a chronic vaginitis clinic.
Infect Dis Obstet Gynecol, 4 (1996), pp. 77-84
[131.]
J.G. Lossick.
Chemotherapy of nitroimidazole resistant vaginal trichomoniasis.
Acta Univ Carol Biol, 30 (1986), pp. 533-545
[132.]
S.A. Foster, O.G. Ramírez, A.H. Rapaport.
Metronidazole and trichomanal vaginitis.
Am J Obstet Gynecol, 87 (1963), pp. 1.013-1.023
[133.]
W.F. Peterson, F.W. Hansen, J.E. Stauch, C.D. Ryder.
Trichomonal vaginitis: Epidemiology and therapy.
Am J Obstet Gynecol, 97 (1967), pp. 472-478
[134.]
F.J. Kazmier.
A significant interaction between metronidazole and warfarin.
Mayo Clin Proc, 51 (1976), pp. 782-784
[135.]
K.W. Garey, K.A. Rodvold.
Disulfiram reactions and anti-infective agents.
Infect Med, 16 (1999), pp. 741-744
[136.]
R. Sharma, J. Pickering, W.M. McCormack.
Trichomoniasis in a postmenopausal woman cured after discontinuation of estrogen replacement therapy.
Sex Transm Dis, 24 (1997), pp. 543-545
[137.]
M. Rustia, P. Shubik.
Induction of lung tumors and maligmant lymphomas in mice by metronidazole.
J Natl Cancer Inst, 48 (1972), pp. 721-729
[138.]
C.M. Beard, K.L. Noller, W.M. O’Fallon, L.T. Kurland, M.B. Dockerty.
Lack of evidence for cancer due to use of metronidazole.
N Engl J Med, 301 (1979), pp. 519-522
[139.]
C.M. Beard, K.L. Noller, W.M. O’Fallon, L.T. Kurland, D.C. Dahlin.
Cancer after exposure to metronidazole.
Mayo Clin Proc, 63 (1988), pp. 147-153
[140.]
M.D. Pearlman, C. Yashar, S. Ernst, W. Solomon.
An incremental dosing protocol for women with severe vaginal trichomoniasis and adverse to metronidazole.
Am J Obstet Gynecol, 174 (1996), pp. 934-936
[141.]
H.P. Legal.
The treatment of trichomonas and candida vaginitis with clotrimazole vaginal tablets.
Postgrad Med, 50 (1974), pp. 81S-83S
[142.]
M.F. Rein, M. Müller.
Trichomonas vaginalis and tricomoniasis.
Sexually Transmitted Diseases (2nd ed.), pp. 481-492
[143.]
L. Heisterberg.
Placental transfer of metronidazole in the first trimester pregnancy.
J Perinat Med, 12 (1984), pp. 43-45
[144.]
B.J. Struthers.
Metronidazole appears not to be a human teratogen: review of the literature.
Infect Dis Obstet Gynecol, 5 (1997), pp. 326-335
[145.]
G.G.G. Donders.
Treatment of sexually transmitted bacterial diseases in pregnant women.
Drugs, 59 (2000), pp. 477-485
[146.]
E.L. Cornell, L.J. Goodman, M.M. Mathies.
The culture, incidence and treatment of Trichomonas vaginalis.
Am J Obstet Gynecol, 22 (1931), pp. 360
[147.]
L. Farouk, A. Salihi, J.P. Curran.
Neonatal Trichomonas vaginalis: Report of three cases and a review of the literature.
Pediatrics, 53 (1974), pp. 196-200
[148.]
I.S. Danesh, J.M. Stephen, J. Gorbach.
Neonatal Trichomonas vaginalis infection.
J Emergency Med, 13 (1995),
[149.]
J.A. Waitz, E.L. Moss, M.J. Weinstein.
Chemotherapeutic evaluation of clotrimazole (Baby b 5097, 1 (o-chloro-diphenylbenzyl) imidazole).
Appl Microbiol, 22 (1971), pp. 891-898
[150.]
J.D. Schnell.
The incidence of vaginal candida and trichomonas infections and treatment of trichomonas vaginitis with clotrimozale.
Postgrad Med J, 50 (1974), pp. 79S-81S
[151.]
H. Lohmeyer.
Treatment of candidiasis and trichomoniasis of the female genital tract.
Postgrad Med J, 50 (1974), pp. 78S-79S
[152.]
G. Saurina, L. DeMeo, W.M. Mc Cormack.
Cure of metronidazole- and Trinidazole- resistant trichomoniasis with use of high-dose oral and intravaginal tinidazole.
Clin Infect Dis, 26 (1998), pp. 1.238-1.239
[153.]
M. Dumont, B. Croizat, P. Douillet.
Traitement des vaginites à trichomonas par la paromomycine.
Gynécologie Pratique, 15 (1964), pp. 247-251
[1.]
H. Spitzbart.
Ist Paramomycin zur Behandlung der Trichomonaden-Infecktion ver der Frau geeignet? II. Klinische Erfahrungen.
Zentralbl Gynakol, 88 (1996), pp. 563-566
[1.]
J.N. Krieger, M.F. Rein.
Zinc sensitivity of Trichomonas vaginalis. In vitro studies and clinical implications.
J Infect Dis, 146 (1982), pp. 341-345
[156.]
B.J. Andrews, H. Mylwaganam, A. Yule.
Sensitivity of Trichomonas vaginalis, Tritrichomonas foetus and Giardia intestinalis to bacitracin and its zinc salt in vitro.
Trans R Soc Trop Med Hyg, 88 (1994), pp. 704-706
[1.]
E.T. Houang, Z. Ahmet, A.G. Lawrence.
Successful treatment of four patients with recalcitrant vaginal trichomoniasis with a combination of zinc sulfate douche and metronidazole therapy.
Sex Transm Dis, 24 (1997), pp. 116-119
[158.]
F. Willmont, J. Say, D. Downey, A. Hookham.
Zinc and recalcitrant trichomoniasis.
Lancet, 1 (1983), pp. 1.053
[159.]
J. Weihe, C. Metelmann, K. Borner, J. Meingassner, C.E. Orfanos.
Metronidazole- resistant trichomoniasis and successful therapy following high dosage.
Hautarzt, 39 (1988), pp. 237-239
[160.]
N.M. Antonelli, S.J. Diehl, J.W. Wright.
Intravaginal nonoxynol-9 versus oral metronidazole in the treatment of trichomoniasis ACOG 47th Annual Clinical Meeting (May 15-19), Philadelphia (Pennsylvania) 1999.
Obstet Gynecol, 4 (1999), pp. 58S-59S
[161.]
M.J. Farthing, P.M. Inge, R.M. Pearson.
Effect of D-propanolol on growth and motility of flagellate protozoa.
J Antimicrob Chemother, 20 (1987), pp. 519-522
[162.]
R. Pavic, L. Stojkovic.
Vaccination with Solco Trichovac. Immunological aspects of a new approach for therapy and prophylaxis of trichomoniasis in women.
Gynakol Rundsch, 23 (1983), pp. 27-38
[163.]
F. Bonilla-Musoles, J.M. Sánchez-Pens, A. Pellices, F. Guevara, W.J. Ziegler.
A vaccine against vaginal trichomoniasis in humans. A temporary solution of the problem?.
Rev Esp Obstet Ginecol, 43 (1983), pp. 777-789
[164.]
R. Milovanovic, R. Crcic, L. Stojkovic.
Serological study with Solco-Trichovac, a vaccine against Trichomonas vaginalis infection in women.
Gynakol Rundsch, 23 (1983), pp. 39-45
[165.]
J.F. Alderete.
Does lactobacilli vaccines for trichomoniasis, Solco-Trichovac, induce antibody reactive with Trichomonas vaginalis?.
Genitourin Med, 64 (1988), pp. 118-123
[166.]
A. Gombosová, P. Demes, M. Valent.
Immunotherapeutic effect of the lactobacillus vaccine, Solco-Trichvac, in trichomoniasis is not mediated by antibodies cross reacting with Trichomonas vaginalis.
Genitourin Med, 62 (1986), pp. 107-110
[167.]
C.A. Wong, D. Wilson, T.A. Chew.
Povidone-iodine in the treatment of metronidazole- resistant Trichomonas vaginalis.
Aust N Z J Obstet Gyneaecol, 30 (1990), pp. 169-171
[168.]
M.T. Brown.
Trichomoniasis.
Practitioner, 209 (1972), pp. 639-644
[169.]
L.C. Ford, H.A. Hammill, R.J. DeLange, D.A. Bruckner, F. Suzuki-Chavez, K.L. Mickus, T.B. Lebherz.
Determination of estrogen and androgen receptors in Trichomonas vaginalis and the effects of antihormones.
Am J Obstet Gynecol, 156 (1987), pp. 1.119-1.121
[170.]
P. Cappuccinely, C. Lattes, I. Cagliani, A. Negro Ponzi.
Features of intravaginal Trichomonas vaginalis infection in the mouse and the effect of oestrogen treatment and immunodepression.
G Batteriol Virol Immunol, 67 (1974), pp. 31-40
[171.]
G. Maestrone, R. Semar.
Experimetnal intravaginal infection with Trichomonas foetus in guinea pigs.
Chemotherapy, 12 (1967), pp. 137-145
[172.]
T. Azuma.
A study of the parasitizing condition of Trichomonas vaginalis with especial reference to the relationship between estrogen and the growth of Trichomonas vaginalis.
J Jap Obstet Gynec Soc, 15 (1968), pp. 168-172
[173.]
I.F. Stein, E.J. Cope.
Trichomonas vaginalis (Donné).
Am J Obstet Gynecol, 25 (1993), pp. 819-825
[174.]
M.G. Martinitti, D. Savoia.
Effect of some steroid homones on the growth of Trichomonas vaginalis.
G Gatteriol Virol Immunol, 78 (1985), pp. 52-59
[175.]
F.L. Al-Salihi, J.P. Curran, J. Wang.
Neonatal Trichomonas vaginalis: report of three cases and review of the literature.
Pediatrics, 53 (1974), pp. 196-200
[176.]
P.P. Walker, R.E. Hall, J.D. Wilson.
Arsenical pessaries in the treatment of metronidazole-resistant Trichomonas vaginalis.
Int J STD & AIDS, 8 (1997), pp. 437
[177.]
P.G. Watson, R.S. Pattman.
Arsenical pessaries in the successful elimination of metronidazole-resistant Trichomonas vaginalis.
Int J STD & AIDS, 7 (1996), pp. 296-297
[178.]
R.S. Pattman, M.S. Sprott, A.M. Kearns, M. Earnshaw.
Failure of mebendazole to cure trichomonal vaginitis resistant to metronidazole: case reports.
Genitourin Med, 65 (1989), pp. 274-275
[179.]
W. Lotcki, K. Kuczynska, A. Malarewicz.
Nitrofurantoin in the treatment of vaginal trichomoniasis in women.
Wiad Parazytol, 15 (1969), pp. 385-386
[180.]
J.S. Ryu, J.W. Park, D.Y. Min.
Effect of sodium nitrite on Trichomonas vaginalis.
Korean J Parasitol, 33 (1995), pp. 349-356
[181.]
R. Romero Cabello, L. Robert Guerrero, M.R. Muñoz García, A. Geyne Cruz.
Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico.
Trans R Soc Trop Med Hyg, 91 (1997), pp. 701-703
[182.]
J.F. Rossignol, H. Maisonneuve.
Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana.
Am J Trop Med Hyg, 33 (1984), pp. 511-512
[183.]
O. Duombo, J.F. Rossignol, H. Pichard, H. Traore, M. Dembele, M. Diakite, F. Traore, D.A. Diallo.
Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa.
Am J Trop Med Hig, 56 (1997), pp. 637-639
[184.]
J.F. Rossignol, H. Hidalgo, M. Feregrino, F. Higuera, W.H. Gomez, J.L. Romero, J. Padierna, A. Gayne, M.S. Ayers.
A double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhea in AIDS patients.
Transc R Soc Trop Med Hyg, 92 (1998), pp. 663-666
[185.]
A. Bicart-Seé, P. Massip, M.D. Linas, A. Datry.
Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS.
Antimicrob Agents Chemother, 44 (2000), pp. 167-168
[186.]
P.B. Mead, D.A. Eschenbanch, J.D. Sobel.
Update on managemente of vaginitis.
Contemporary OB/GYN, 44 (1999), pp. 26-47
[187.]
A.M. Gülmezoglu, F. Forna.
Interventions for treating trichomoniasis in women. (Cochrane Review).
The Cochrane Library, issue 1,
[188.]
F. Gorlero, P. Bosco, M. Barbieri, C. Bertulessi, L. Pulici, L. Polvani, L. De Cecco.
Fenticonazole ovules in the treatment of vaginal trichomonas infections. A double-blind randomized pilot clinical trail.
Curr Ther Res, 51 (1992), pp. 367-376
[189.]
F. Gorlero, S. Macchiavello, L. Pellegatta, M.L. Airoldi, B. Gaffuri, L. Pulici, L. De Cecco.
Evaluation of the efficacy and torelability of two different dosages of fenticonazole vaginal ovules (600 mg and 1.000 mg) in patients with vaginal trichomoniasis: A controlled, double- blind, randomized clinical trial versus placebo.
Curr Ther Res, 55 (1994), pp. 510-518
[190.]
T.H. Leran, D. Vengadasalam.
Treatment of trichomoniasis with a new anti-protozal compund (ocholoromethy-2-methyl-5-nitro-l-ethanol).
Br J Vener Dis, 49 (1973), pp. 69-71
[191.]
J.K.G. Mati, R.J. Wallace.
The treatment of trichomonal vaginitis using a single dose of tinidazole by mouth.
East Afr Med J, 51 (1974), pp. 883-888
[192.]
P.H. Rees, H.E. McGlashan, V. Mwega.
Single-dose treatment of vaginal trichomoniasis with tinidazole.
East Afr Med J, 51 (1974), pp. 782-785
[193.]
V.E. Aimakhu.
Vaginal trichomoniasis: One stat dose of tinidazole compared with a seven-day course of metronidazole.
West Afr Med J, 23 (1975), pp. 97-100
[194.]
B. Nygaard, H. Kjaersgaard, B. Komer, R. Hammer Jensen.
Single-dose treatment wit ornidazole (Tiberal (R)) and seven-day treatment with metronidazole (Flagyl (R)) in vaginal trichomoniasis.
Ugeskr Laeg, 139 (1977), pp. 524-526
[195.]
J. Lyng, J. Christensen.
A double-blind study of the value of treatment with a single dose tinidazole of partners to female with trichomoniasis.
Acta Obstet Gynecol Scand, 50 (1981), pp. 199-201
[196.]
R. Anjaneylu, S.A. Gupte, D.B. Desai.
Single-dose treatment of trichomonal vaginitis: a comparison of tinidazole and metronidazole.
J Int Med Res, 5 (1977), pp. 438-441
[197.]
G. Gabriel, E. Robertson, R.N. Thin.
Single dose treatment of trichomoniasis.
I. Int Med Res, 10 (1982), pp. 129-130
[198.]
M. Garud, M. Lulla, U. Saraiya, S. Vaidya.
Oral single dose therapy of trichomonal vaginitis: comparison of tinidazole and metronidazole.
J Obstet Gynaecol India, 28 (1978), pp. 347-350
[199.]
H.T.M. Rao, D.R. Shenoy.
Single-dose oral treatment of vaginal trichomoniasis with tinidazole and metronidazole.
J Int Med Res, 6 (1978), pp. 46-49
[200.]
R. Sandvei, K. Hernborg.
Behandling av trichomonas vaginalis.
Tidsskr Nor Loegeforen, 99 (1979), pp. 316-317
[201.]
P. Chaisilwattana, P. Bhiraleus, P. Patanaprnich, C. Bhadrakow.
Double blind comparative study of tinidazole and omidazole as a single dose treatment of vaginal trichomoniasis.
J. Med Assoc Thailand, 63 (1980), pp. 448-452
[202.]
J. Serup, R.H. Jensen.
Treatment of trichomoniasis vaginalis with single oral dose of ornidazole (Tiberal and tinidazole (Fasigyn). A controlled investigation.
Ugeskr Laeg, 140 (1978), pp. 1.483-1.484
[203.]
C.N. Chunge, S. Kangethe, H.O. Pamba, J. Owate.
Treatment of symptomatic trichomoniasis among adult women using oral nitroimidazoles.
East Afr Med J, 69 (1992), pp. 398-401
[204.]
F. Sesti, E. Valli, C. Troisi, F. Ciancio, E. Piccione.
Studio clinico comparativo sull’efficacia terapeutica di tinidazole vs. Ornidazole nel ttrattamento della trichomoniasi vaginale [comparative clinical study of the therapeutic efficacy of tinidazole and ornidazole in the treatment of vaginal trichomoniasis].
Giorn It Ost Gin, 12 (1990), pp. 83-84
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos